The US Centers for Disease Control and Prevention updated its malaria prevention guidance for East Africa on June 4. Atovaquone-proguanil continues as the primary drug for short-term travelers to Kenya, Tanzania and Uganda. Tafenoquine received expanded approval for longer stays up to six months.
Chloroquine resistance remains widespread, so the CDC removed it from recommended options. Travelers must start medication before arrival and continue for seven days after departure. Pharmacies in destination countries cannot reliably supply these specific drugs.
Background shows 2,500 US travelers contracted malaria in East Africa in 2025 despite available prophylaxis. The update follows new clinical trial data published in The Lancet. Health authorities expect the changes to reduce infection rates by 30 percent.
Yellow fever vaccination requirements remain unchanged for the same countries. Mosquito bite prevention with DEET remains essential alongside medication.
What this means for you
Visit a travel clinic at least four weeks before departure to obtain the correct prescription. Choose atovaquone-proguanil for trips under 28 days and discuss tafenoquine for extended itineraries. Start the course exactly as prescribed to ensure full protection.
Pack 30 percent DEET repellent and long clothing for evening activities. Sleep under insecticide-treated nets in rural lodges. Carry a copy of your prescription in case of lost medication.
Review the CDC Travelers' Health website again one week before travel for any last-minute updates.